





Billing and Coding Guide

A useful resource to support reimbursement of GLASSIA® and ARALAST® NP across different sites of care

Please see Indication and Important Safety Information on page 2, and click for Full Prescribing Information for <u>GLASSIA</u> and <u>ARALAST NP</u>.

IMPORTANT SAFETY INFORMATION

Introduction

Product Codes Sample Claim Forms Distribution and Inventory

Product Support

References

Important Safety Information



INDICATION AND LIMITATIONS OF USE:

GLASSIA and **ARALAST NP** are Alpha₁-Proteinase Inhibitors (Human) (Alpha₁-PI) indicated for chronic augmentation therapy in adults with clinically evident emphysema due to severe hereditary deficiency of Alpha₁-PI (alpha₁-antitrypsin deficiency). **GLASSIA** and **ARALAST NP** increase antigenic and functional (anti-neutrophil elastase capacity, ANEC) serum levels and antigenic lung epithelial lining fluid levels of Alpha₁-PI.

- The effect of augmentation therapy with **GLASSIA**, **ARALAST NP**, or any Alpha₁-PI product on pulmonary exacerbations and on the progression of emphysema in Alpha₁-PI deficiency has not been conclusively demonstrated in randomized, controlled clinical trials.
- Clinical data demonstrating the long-term effects of chronic augmentation and maintenance therapy of individuals with **GLASSIA** or **ARALAST NP** are not available.
- **GLASSIA** and **ARALAST NP** are not indicated as therapies for lung disease in patients in whom severe Alpha₁-PI deficiency has not been established.

IMPORTANT SAFETY INFORMATION

Contraindications

- Immunoglobulin A (IgA) deficient patients with antibodies against IgA
- History of anaphylaxis or other severe systemic reaction to Alpha,-PI products.

Warnings and Precautions

Hypersensitivity: GLASSIA and **ARALAST NP** may contain trace amounts of IgA. Patients with known antibodies to IgA have a greater risk of developing severe hypersensitivity and anaphylactic reactions. Closely follow the recommended infusion rate, monitor vital signs continuously, and observe the patient throughout the infusion. If hypersensitivity symptoms occur, discontinue the infusion and administer appropriate emergency treatment. Have epinephrine and/or other appropriate supportive therapy available for any acute anaphylactic or anaphylactoid reaction.

Transmissible Infectious Agents: Because **GLASSIA** and **ARALAST NP** are made from human plasma, they may carry a risk of transmitting infectious agents such as viruses, the variant Creutzfeldt-Jakob disease (vCJD), and theoretically the Creutzfeldt-Jakob disease (CJD) agent and other pathogens. No seroconversions for hepatitis B or C or human immunodeficiency virus or any other known infectious agent were reported with the use of **GLASSIA** or **ARALAST NP** during the clinical trials.

Adverse Reactions

GLASSIA: The serious adverse reaction observed during clinical trials was exacerbation of chronic obstructive pulmonary disease (COPD). The most common adverse reactions (>0.5% of infusions) in clinical trials were headache and upper respiratory infection.

ARALAST NP: Hypersensitivity reactions have been reported in patients following administration of **ARALAST NP**. The most common adverse reactions (>0.5% of infusions) in clinical trials were headache, musculoskeletal discomfort, vessel puncture site bruise, nausea, and rhinorrhea.

Please click for Full Prescribing Information for GLASSIA and ARALAST NP.

Important Safety Information

INTRODUCTION

Product S Codes

Sample Claim Forms Distribution and Inventory Product Support

References

Introduction

Billing and coding for GLASSIA[®] and ARALAST[®] NP might feel complex at first. **Don't worry. We have you covered.**

This resource provides an overview of the current relevant codes, as of [January 2023], that may be potential options for use with **GLASSIA** and **ARALAST NP**.

Alpha-1-antitrypsin (Alpha-1) proteinase inhibitors can be administered in the home setting, hospital, or various medical facilities. This guide will walk you through the information you need to seek reimbursement for the use of these products within these different settings. Takeda

Helpful reminders for submitting claims

- Clarify the payer's coding and clinical documentation requirements, as there may be variations in payer requirements
- Keep in touch with a payer representative who may help clarify problems with the original claim and provide information on current claims as they are processed
- Ensure claims are checked for errors and are accurate and complete before submitting

Please see Indication and Important Safety Information on page 2, and click for Full Prescribing Information for <u>GLASSIA</u> and <u>ARALAST NP</u>.

Coding and coverage policies may change periodically and often without warning. The information provided here should in no way be considered a guarantee of coverage or reimbursement for any product or service.



INTRODUCTION

Product Codes Sample Claim Forms Distribution and Inventory

Product Support

References

Introduction



An Overview of Reimbursement Codes

Below are general definitions of commonly used reimbursement codes.

CODE TYPE	CODE DESCRIPTION
ICD-10-CM	The International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) are diagnostic codes that must be used for all healthcare services provided in the United States. ¹
СРТ	A Current Procedural Terminology (CPT®) code is a 5-digit number used to identify medical services and procedures performed by healthcare professionals (HCPs). These codes are maintained by the American Medical Association (AMA). ²
NDC	A National Drug Code (NDC) is a unique 3-segment number that serves as a universal product identifier for a drug. ³
	Healthcare Common Procedure Coding System (HCPCS) codes are used primarily to identify products, supplies, and services not covered by the CPT code. ⁴
HCPCS	J-codes The most common HCPCS codes are called J-codes, which are used to primarily identify an injectable drug product or biologic. ⁵

Please see Indication and Important Safety Information on page 2, and click for Full Prescribing Information for <u>GLASSIA</u> and <u>ARALAST NP</u>.

Coding and coverage policies may change periodically and often without warning. The information provided here should in no way be considered a guarantee of coverage or reimbursement for any product or service.



PRODUCT CODES Sample Claim Forms Distribution and Inventory Product Support

References

Product Codes

• • • • • •



ICD-10-CM Diagnostic Codes⁶

The following table lists commonly used codes for GLASSIA® and ARALAST® NP.

ICD-10-CM CODES	CODE DESCRIPTION
E88.01	Alpha-1-antitrypsin deficiency
J43.1	Panlobular emphysema
J43.2	Centrilobular emphysema
J43.8	Other emphysema
J43.9	Emphysema, unspecified

Please see Indication and Important Safety Information on page 2, and click for Full Prescribing Information for <u>GLASSIA</u> and <u>ARALAST NP</u>.

Coding and coverage policies may change periodically and often without warning. The information provided here should in no way be considered a guarantee of coverage or reimbursement for any product or service.



PRODUCT Sa CODES C

Sample Claim Forms Distribution and Inventory

References

Product

Support

Product Codes

• • • • • •



CPT Codes for Diagnostic Testing⁷

These CPT codes are commonly used for diagnosing Alpha-1 deficiency.

CPT CODES	CODE DESCRIPTION
82103	Alpha-1-antitrypsin total
82104	Alpha-1-antitrypsin phenotype
81332	The lab analyst performs the technical lab test to detect the presence of common changes in the gene for serpin peptidase inhibitor, clade A, Alpha-1 antiproteinase, antitrypsin, member 1, also known as SERPINA1
82542	Column chromatography/mass spectrometry
81479	Molecular pathology procedure that does not have a specific code

Please see Indication and Important Safety Information on page 2, and click for Full Prescribing Information for <u>GLASSIA</u> and <u>ARALAST NP</u>.

Coding and coverage policies may change periodically and often without warning. The information provided here should in no way be considered a guarantee of coverage or reimbursement for any product or service.



Important Safety Introduction Control Control

PRODUCT S

Sample Claim Forms Distribution and Inventory

Product Codes

.....

Product

Support



CPT Administration Codes⁷

The following table lists the possible commonly used CPT codes applicable for GLASSIA® and ARALAST® NP infusion.

CPT CODES	CODE DESCRIPTION
96365	Intravenous (IV) infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour
96366	IV infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour (list separately in addition to code for primary procedure)
96367	IV infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour
96523	Irrigation of implanted venous access device for drug delivery systems
99070	Additional supplies provided over and above those usually included with a specific service, such as drugs, IV catheters, or trays
99072	Additional supplies, materials, and clinical staff time over and above those usually included in an office visit or other nonfacility service(s), only when performed during a Public Health Emergency as defined by law, due to respiratory-transmitted infectious disease

Please see Indication and Important Safety Information on page 2, and click for Full Prescribing Information for <u>GLASSIA</u> and <u>ARALAST NP</u>.

Coding and coverage policies may change periodically and often without warning. The information provided here should in no way be considered a guarantee of coverage or reimbursement for any product or service.



Sample I Claim Forms a

Distribution and Inventory

Product

Support

Product Codes

• • • • • •



HCPCS CODES J-codes⁸⁻¹⁰

The following table lists the possible commonly used J-codes for GLASSIA® and ARALAST® NP.

DRUG	J-CODES	
GLASSIA (solution)	J0257	Injection, Alpha-1 proteinase inhibitor (human), (GLASSIA), 10 mg*
ARALAST NP (powder)	J0256	Injection, Alpha-1 proteinase inhibitor (human), not otherwise specified, 10 mg*

NDC^{8,10}

The following table lists the possible commonly used NDCs for GLASSIA and ARALAST NP.

DRUG	NDC	1 BILLABLE UNIT*	SDV SIZE
GLASSIA (solution)	0944-2884-01	10 mg	1 g/50 mL
ARALAST NP	0944-2814-01	10 mg	0.5 g/25 mL
(powder)	0944-2815-01	10 mg	1 g/50 mL

*To convert the dosage in grams to International Units (IU), 1 g = 1,000 IU. For the billable units above, 10 mg = 10 IU. SDV=single-dose vial.

Please see Indication and Important Safety Information on page 2, and click for Full Prescribing Information for <u>GLASSIA</u> and <u>ARALAST NP</u>.

Coding and coverage policies may change periodically and often without warning. The information provided here should in no way be considered a guarantee of coverage or reimbursement for any product or service.



Important Safety	Introduction	PROD
Information	Introduction	CODE

RODUCT S

Sample Claim Forms

Distribution and Inventory

Product Codes



Product

Support

Hospital Revenue Codes¹¹

The following table lists the possible commonly used hospital revenue codes for the CMS-1450 form (hospital outpatient).

REVENUE CODES	CODE DESCRIPTION
260	IV therapy
261	IV therapy, infusion pump
262	IV therapy, pharmacy services
263	IV therapeutic drug, supply, and delivery
264	IV therapy, supplies
269	IV therapy, other

Please see Indication and Important Safety Information on page 2, and click for Full Prescribing Information for <u>GLASSIA</u> and <u>ARALAST NP</u>.

Coding and coverage policies may change periodically and often without warning. The information provided here should in no way be considered a guarantee of coverage or reimbursement for any product or service.



luction PRODUCT CODES

Sample Claim Forms Distribution and Inventory

Product Support

References

Product Codes

• • • • • •



Recommended Dosing Regimen

The dose prescribed follows the FDA-approved labeling based on the patient's confirmed diagnosis.

GLASSIA®8

- 60 mg/kg body weight administered once weekly by IV infusion
- Administer at a rate not to exceed
 0.2 mL/kg body weight/minute depending on patient response and comfort

ARALAST[®] NP¹⁰

- 60 mg/kg body weight administered once weekly by IV infusion
- Administer at a rate not to exceed
 0.2 mL/kg body weight/minute and as determined by the response and comfort of the patient

Billing for Home Infusion Therapy Services¹²

The table below shows the 15-minute time increments that HCPs may use to report visit length (15 minutes = 1 unit).

UNIT		UNIT	
1	≥8 minutes through 22 minutes	6	= 83 minutes to <98 minutes
2	= 23 minutes to <38 minutes	7	= 98 minutes to <113 minutes
3	= 38 minutes to <53 minutes	8	= 113 minutes to <128 minutes
4	= 53 minutes to <68 minutes	9	= 128 minutes to <143 minutes
5	= 68 minutes to <83 minutes	10	= 143 minutes to <158 minutes

Please see Indication and Important Safety Information on page 2, and click for Full Prescribing Information for <u>GLASSIA</u> and <u>ARALAST NP</u>.

Coding and coverage policies may change periodically and often without warning. The information provided here should in no way be considered a guarantee of coverage or reimbursement for any product or service.



Important Safety In Information

Introduction

Product Codes

SAMPLE CLAIM FORMS Distribution and Inventory


Product Support

References

Sample Claim Forms



This form, also known as the UB-04, is the standard claim form to bill Medicare Fee-for-Service.



A

REVENUE CODES AND DESCRIPTIONS

On line 42, enter the revenue codes that correspond to the HCPCS or CPT codes outlined on line 44. For line 43, enter a revenue descriptor (optional).



PRODUCT AND PROCEDURE CODES

On line 44, indicate the appropriate CPT codes, HCPCS codes, and modifiers as required by Medicare or other payer.



TOTAL CHARGES

Use line 47 to enter the total amount charged for each line of service.

D

ADMIT DIAGNOSIS

On line 69, indicate diagnosis using appropriate ICD-10-CM codes. Code to the highest level of specificity for the date of service and enter diagnoses in priority order.

Please see Indication and Important Safety Information on page 2, and click for Full Prescribing Information for <u>GLASSIA</u> and <u>ARALAST NP</u>.

Coding and coverage policies may change periodically and often without warning. The information provided here should in no way be considered a guarantee of coverage or reimbursement for any product or service.



Important Safety Int Information

Introduction

Product Codes

SAMPLE CLAIM FORMS

Distribution and Inventory

References

Sample Claim Forms

Sample Claim Form CMS-1500 (Physician's Office)

The CMS-1500 claim form is the standard claim form used to bill many government and private insurers.

APPROVED BY NATIONAL UNIFORM CLAIM COMMITTEE (DRM									
	NUCC) 02/12									PICA
1. MEDICARE MEDICAID TRICARE	CHAMP	A GRO	OUP NUTH PLAN	FECA BLK LUNG (ID#)	OTHER	1a. INSURED'S I.D	NUMBER		(For	r Program in Item 1)
(Medicare#) (Medicaid#) (ID#/DcD#) 2. PATIENT'S NAME (Last Name, First Name, Middle Initial)	(Momber)				((D#) EX	4. INSURED'S NAM				
2. PATIENT S NAME (Last Name, Prist Name, Middle Initial)		S. PATIENT	DO YY	_ M	F	4. INSURED S NAM	IC (Last rea	me, First Name	, MIGOR	rinoal)
5. PATIENT'S ADDRESS (No., Street)		_	RELATIONSH			7. INSURED'S ADD	RESS (No.	, Street)		
CITY	STATE	Self	Spouse P		Other	CITY				STATE
CITY	STATE	8. HESEHV	ED FOR NUCC	JUSE		CITY				STATE
ZIP CODE TELEPHONE (Include Are	a Code)	1				ZIP CODE		TELEPHO	NE (Incl	ude Area Code)
()								()	
 OTHER INSURED'S NAME (Last Name, First Name, Midd) 	e Initial)	10. IS PATH	ENT'S CONDIT	ION RELAT	ED TO:	11. INSURED'S PO	LICY GRO	UP OR FECA I	UMBER	1
. OTHER INSURED'S POLICY OR GROUP NUMBER		a. EMPLOY	MENT? (Curre	nt or Previou	s)	a. INSURED'S DAT	E OF BIRT	н		SEX
. RESERVED FOR NUCC USE		b. AUTO AG	YES	NO					и 🗌	F
A RESERVED FOR NOUS USE		D. AUTO AC	YES		ACE (State)	b. OTHER CLAIM I	D (Designa	ted by NUCC)		
. RESERVED FOR NUCC USE		c. OTHER /				c. INSURANCE PL	AN NAME C	R PROGRAM	NAME	
			YES	NO NO						
J. INSURANCE PLAN NAME OR PROGRAM NAME		10d. CLAIM	CODES (Desi	phated by NL	ICC)	d. IS THERE ANOTHER HEALTH BENEFIT PLAN?			no Di Qai anvi Qui	
READ BACK OF FORM BEFORE 2. PATIENT'S OR AUTHORIZED PERSON'S SIGNATURE	COMPLETIN	G & SIGNING	THIS FORM.			13. INSURED'S OR	AUTHORI	ZED PERSON	S SIGN	ATURE I authorize
 PATIENT'S OH AUTHORIZED PERSON'S SIGNATURE to process this claim. I also request payment of government below. 	benefits either	release of any r to myself or to	the party who	accepts assig	necessary inment	payment of med services describ	ical benefit ed below.	s to the unders	igned ph	sysician or supplier for
SIGNED			ATE			SIGNED				
14. DATE OF CURRENT ILLNESS, INJURY, or PREGNANC	Y (LMP) 15	OTHER DATI	6				IT UNABLE	TO WORK IN	CURRE	NT OCCUPATION
QUAL.	QU	JAL	MM	DD	YY	16. DATES PATIENT UNABLE TO WORK IN CURRENT OCCUPATION MM DD YY MM DD YY FROM TO				
17. NAME OF REFERRING PROVIDER OR OTHER SOURC		a. b. NPI				18. HOSPITALIZAT	DD DD		O CURR MM	DD YY
9. ADDITIONAL CLAIM INFORMATION (Designated by NU		a NPI				20. OUTSIDE LAB	6		CHARG	ES
						YES	NO			
21. DIAGNOSIS OR NATURE OF ILLNESS OR INJURY Rel		vice line below	(24E) ICD		A)	22. RESUBMISSIO	N	ORIGINAL	REF. NO	5.
A.L B.L E.L F.I	C. L		-	D. L		23. PRIOR AUTHO	RIZATION	NUMBER		
. L J. L	к. L		_	LL						
24. A. DATE(S RVICE B. C. From To PLACE OF M DD YY DD YY SERVICE EMG	D. PROCE (Expl	lain Ur	VICES, OR SU cumstances) MODIFIE		E. DIAGNOSIS	F. \$ CHARGES	G. DAYS OR	Family ID.		J. RENDERING PROVIDER ID. #
M DD YY DD YY SERVICE EMG	CPINIC	1.5	MODIFIE		(F)	SCHAHGES	Ť	Plan QUAL		PHOVIDER ID. #
								NPI		
	1	1						NPI		
	-	-	1					NP		
								NPI	-	
1 1 1 1 1 1 1 1 1	1					1	1	NPI		
	-	_		-				NPI		
								NPI		
1 1 1 1 1 1 1	1						-	1 1 1 1		
25. FEDERAL TAX I.D. NUMBER SSN EIN 26	PATIENT'S	ACCOUNT NO). 27. A	CCEPT ASS	GNMENT?	28. TOTAL CHARG	E I	NPI 29. AMOUNT P	AID	30. Revd for NUCC
				YES	NO	s		s	1	
1. SIGNATURE OF PHYSICIAN OR SUPPLIER 32	SERVICE FA	ACILITY LOCA	ATION INFORM	IATION		33. BILLING PROV	IDER INFO	& PH # ()	
31. SIGNATURE OF PHYSICIAN OR SUPPLIER 32 INCLUDING DEGREES OR CREDENTIALS (i certify that the statements on the reverse apply to this bill and are made a part thereof.)										
INCLUDING DEGREES OR CREDENTIALS (I certify that the statements on the reverse	p.1	01	b.			a. ND		0		



DIAGNOSIS CODE

Product

Support

In Box 21, indicate the corresponding ICD-10-CM code for the patient's diagnosis.



PRODUCT INFORMATION

Box 24 is for supplemental information, such as the NDC. Verify information requirements with the payer.



DATE OF SERVICE

When required by payers to provide the NDC in Box 24A, enter the dates of service that correspond to the code.



PRODUCT AND PROCEDURE CODES

In Box 24D, document the HCPCS code for the infusion product and the CPT code representing the procedure performed.



DIAGNOSIS POINTER

Specify the diagnosis in Box 21 related to each CPT/HCPCS code listed in Box 24D. This may be indicated as a letter or number, depending on the payer.

SERVICE UNITS

In Box 24G, indicate the appropriate number of service units that should reflect the actual number of medication doses provided.

Please see Indication and Important Safety Information on page 2, and click for Full Prescribing Information for <u>GLASSIA</u> and <u>ARALAST NP</u>.

Coding and coverage policies may change periodically and often without warning. The information provided here should in no way be considered a guarantee of coverage or reimbursement for any product or service.



Important Safety Information Introduction

Product Sa Codes Cl

Sample Claim Forms

DISTRIBUTION Product AND INVENTORY Support

References

Distribution and Inventory



Select Specialty Pharmacies Are Authorized Distributors for Home Infusion

If you and your patient opt for home infusion, GLASSIA® and ARALAST® NP are available through a specialty pharmacy provider (SPP). The following SPPs are authorized to dispense GLASSIA and ARALAST NP:

- [Accredo® Specialty Pharmacy]
- [AllianceRx Walgreens Pharmacy]
- [AvevoRX[®]]
- [CVS Health®]
- [CenterWell Pharmacy™] (formerly Humana RightSource®)
- [Option Care Health®]
- [Optum[®] Infusion Pharmacy]

ORDERING INFORMATION:

GLASSIA NDC......0944-2884-01

GLASSIA J-code J0257

ARALAST NP NDC (0.5 g/25 mL)...0944-2814-01

ARALAST NP NDC (1 g/50 mL)0944-2815-01

ARALAST NP J-code.....J0256

The SPPs listed above are national distributors of GLASSIA and ARALAST NP. You can also inquire with a regional SPP about acquiring Takeda Alpha-1 proteinase inhibitor treatments. Work with your patients to determine which SPP is appropriate for their circumstances.

In-Suite Infusion Can Be Purchased Directly From Takeda

To determine the number of vials needed to fill your patient's weekly dose, please contact Takeda Medical Information at 1-877-TAKEDA-7 or medinfoUS@takeda.com.

For direct ordering information about GLASSIA or ARALAST NP, please contact Takeda Customer Care.

[1-800-423-2090], Monday through Friday, 8:00 AM to 7:00 PM ET

Note that certain ancillary infusion supplies may be needed for infusion but are not available for purchase through Takeda.

Please see Indication and Important Safety Information on page 2, and click for Full Prescribing Information for <u>GLASSIA</u> and <u>ARALAST NP</u>.

Coding and coverage policies may change periodically and often without warning. The information provided here should in no way be considered a guarantee of coverage or reimbursement for any product or service.



Introduction

Product Sa Codes Cla

Sample Claim Forms Distribution and Inventory PRODUCT SUPPORT

References

PnePath[°]



OnePath is CO-PAY ASSISTANCE.

The OnePath Co-Pay Assistance Program may help cover certain out-of-pocket treatment costs for eligible commercially insured patients prescribed GLASSIA® [Alpha₁-Proteinase Inhibitor (Human)] or ARALAST® NP [Alpha₁-Proteinase Inhibitor (Human)] who are enrolled in OnePath.*

The following are covered up to the program maximum and may be paid directly to the provider:

- 100% of eligible out-of-pocket costs related to your treatment, which may include deductibles, co-pays, and co-insurance
- Out-of-pocket costs of eligible infusion charges, where applicable by law

At a minimum, to be eligible for the program, a patient must:

- Be enrolled in OnePath
- Have commercial insurance



Other eligibility requirements may apply.

*IMPORTANT NOTICE: The OnePath Copay Assistance Program (the Program) is not valid for prescriptions eligible to be reimbursed, in whole or in part, by Medicaid, Medicare (including Medicare Part D), Tricare, Medigap, VA, DoD, or other federal or state programs (including any medical or state prescription drug assistance programs). No claim for reimbursement of the out-of-pocket expense amount covered by the Program shall be submitted to any third party payer, whether public or private. The Program cannot be combined with any other rebate/coupon, free trial, or similar offer. Copayment assistance under the Program is not transferable. The Program only applies in the United States, including Puerto Rico and other U.S. territories, and does not apply where prohibited by law, taxed, or restricted. This does not constitute health insurance. Void where use is prohibited by your insurance provider. If your insurance situation changes you must notify the Program immediately at 1-866-888-0660. Coverage of certain administration charges will not apply for patients residing in states where it is prohibited by law. Takeda reserves the right to rescind, revoke, or amend the Program at any time without notice.

Introduction

Product Codes

Sample Claim Forms Distribution and Inventory

PRODUCT SUPPORT

References

PnePath

OnePath is

PERSONALIZED PRODUCT SUPPORT FOR YOUR PATIENTS.

The Takeda OnePath program provides a range of product support services for your patients prescribed GLASSIA® [Alpha,-Proteinase Inhibitor (Human)] or ARALAST® NP [Alpha,-Proteinase Inhibitor (Human)].

From the moment your patients enroll in OnePath, a dedicated Patient Support Manager will work with them one-on-one to help them access their prescribed Takeda medication.

Learn more at OnePath.com

OnePath helps your patients and caregivers



Navigate the health insurance process



Co-Pay Assistance Program (if eligible) or discuss financial assistance options



Enroll in the OnePath Coordinate medication delivery with various sites of care such as hospital-owned specialty pharmacies, home care providers, and infusion centers (if applicable)



Receive free self-administration training with a nurse (if applicable)



Learn about additional support, education, and community resources

For more information, please contact OnePath at 1-866-888-0660 Monday through Friday, 8:30 AM to 8:00 PM ET, or visit <u>OnePath.com</u>.

Access the OnePath Start Form for GLASSIA and ARALAST NP.



Introduction

Product Codes Sample Claim Forms Distribution F and Inventory S

Product Support

References



- 1. Centers for Disease Control and Prevention. International Classification of Diseases, (ICD-10-CM/PCS) transition – background. Reviewed November 6, 2015. Accessed January 17, 2023. https://www.cdc.gov/nchs/icd/icd10cm_pcs_background.htm.
- 2. American Medical Association. CPT[®] overview and code approval. Accessed January 17, 2023. https://www.ama-assn.org/practice-management/cpt/cpt-overview-and-code-approval.
- **3.** United States Food and Drug Administration. National Drug Code database background information. Accessed January 17, 2023. https://www.fda.gov/drugs/development-approval-process-drugs/ national-drug-code-database-background-information.
- **4.** Centers for Medicare and Medicaid Services. HCPCS coding questions. Accessed January 17, 2023. https://www.cms.gov/Medicare/Coding/MedHCPCSGenInfo/HCPCS_Coding_Questions.
- 5. HCPCScodes.org. 2019 HCPCS codes: J codes. Accessed January 17, 2023. https://hcpcscodes.org/jcodes.
- 6. ICD.Codes. ICD-10-CM chapters. Accessed January 17, 2023. https://icd.codes/icd10cm.
- 7. American Academy of Professional Coders. CPT codes lookup. Accessed January 17, 2023. https://www.aapc.com/codes/cpt-codes-range.
- 8. GLASSIA Prescribing Information. Baxalta US Inc. 2017.
- **9.** American Academy of Professional Coders. HCPCS codes lookup. Accessed January 17, 2023. https://www.aapc.com/codes/hcpcs-codes-range.
- 10. ARALAST NP Prescribing Information. Baxalta US Inc. 2018.
- **11.** CIGNA. *Revenue Code List-CPT-HCPCS*. Accessed January 17, 2023. https://static.cigna.com/ assets/chcp/pdf/resourceLibrary/medical/revenue-code-list-requiring-cpt-and-hcps-codes-foroutpatient-facility-claims.pdf.
- **12.** Centers for Medicare and Medicaid Services. *CMS Manual System*. Accessed January 17, 2023. https://www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/downloads/R2121CP.pdf.

Please see Indication and Important Safety Information on page 2 and click for Full Prescribing Information for <u>GLASSIA</u> and <u>ARALAST NP</u>.

Coding and coverage policies may change periodically and often without warning. The information provided here should in no way be considered a guarantee of coverage or reimbursement for any product or service.





©2023 Takeda Pharmaceuticals U.S.A., Inc., 300 Shire Way, Lexington, MA 02421. 1-877-TAKEDA-7 (1-877-825-3327). All rights reserved. TAKEDA* and the TAKEDA Logo* are registered trademarks of Takeda Pharmaceutical Company Limited. GLASSIA* is a registered trademark of Kamada Ltd., and used under license. ARALAST* is a registered trademark of Baxalta Incorporated. ONEPATH* and the ONEPATH Logo* are registered trademarks of Shire Human Genetic Therapies, Inc. US-XMP-1304v3.0 05/23